Related Experiment Video

Updated: Apr 3, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer

Liangqing Ge1, Ruizheng Shi2

  • 1Department of Cardiovascular Medicine, Xiangya Hospital, Central South University Changsha 410008, Hunan, China ; Department of Cardiovascular Medicine, The first people's hospital of Changde city Changde 415000, Hunan, China.

International Journal of Clinical and Experimental Medicine
|September 18, 2015
PubMed

Insights

Molecular targeted therapies like EGFR-TKI and ALK/ROS1 inhibitors significantly improve outcomes for non-small cell lung cancer (NSCLC) patients compared to traditional chemotherapy, though resistance remains a challenge.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
  • Conventional chemotherapy offers limited efficacy and significant toxicity in advanced NSCLC.
  • The emergence of molecular targeted therapies has revolutionized NSCLC treatment paradigms.

Purpose of the Study:

  • To review the mechanism and clinical application of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) and Anaplastic Lymphoma Kinase/ROS1 (ALK/ROS1) inhibitors in NSCLC.
  • To evaluate the impact of these targeted agents on patient outcomes compared to chemotherapy.
  • To identify current challenges and future research directions in molecular targeted therapy for NSCLC.

Main Methods:

  • Comprehensive literature search of PubMed database for relevant studies.
  • Review of preclinical and clinical data on EGFR-TKI and ALK/ROS1 inhibitors.
  • Analysis of efficacy endpoints including progression-free survival (PFS) and objective response rate (ORR).

Main Results:

  • EGFR-TKI and ALK/ROS1 inhibitors demonstrate superior efficacy over conventional chemotherapy in advanced NSCLC.
  • Significant improvements observed in progression-free survival (PFS) and objective response rate (ORR).
  • Enhanced quality of life reported in patients treated with targeted therapies.

Conclusions:

  • Molecular targeted therapy, including EGFR-TKI and ALK/ROS1 inhibitors, is a crucial therapeutic strategy for managing NSCLC.
  • Despite advancements, challenges such as acquired resistance necessitate ongoing research.
  • Further investigation into the role of molecular targeted therapy in NSCLC initiation and progression is warranted.
Keywords:
ALK/ROS1 inhibitorsEGFR-TKI inhibitorsnon-small cell lung cancer

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
651